Inhibition of FASN—a central enzyme in both de novo palmitic acid synthesis and protein palmitoylation—using the selective inhibitor TVB-3166 resulted in downregulation of the Akt–S6 signaling axis and reduced expression of the transcription factor Gli1, thereby significantly impairing the survival of AML cells. Here, AKT1 is linked to acute myeloid leukemia.